³X«È Åwªï±z!   ·|­ûµn¤J


 ¦^¥D­¶  ¡÷    ¥Ö½§¬ì*°©¬ì¸ê°T  ¡÷  ¥»½g¥DÃD¡GÃþ­·Àã



 
¡i¤W¤@½g¡j[ ÀVªÓµmµh ] ¡i¤U¤@½g¡j[ ªvÀø¬õ´³¯T½H «¶¹ç¨ü­«µø ]

    [¤À¨É]    Ãþ­·Àã

    yoyo   µoªí©ó 2007/7/1 10:14:56



µo¯f­ì¦](Etiology) Ãþ­·Àã©ÊÃö¸`ª¢ªº¯f¦]ÁöµMÁÙ¤£¤Q¤À²M·¡,¦ý¬O¦]·P¬V¦Ó¤Þ°_ªº¦ÛÅé§K¬Ì§@¥Î, «h¬O¦h¼Æ¬ã¨sªÌ©Ò¦@¦P±µ¨üªº­P¯f¾÷Âà.¨ä·P¬V­ì¥]¬A:Mycoplasma, Epstein-Barr virus, cytomegalovirus, parvovirus, rubella virusµ¥. ¬°¦ó³o¨Ç·P¬V·|¾É­PÃö¸`ª¢, «h¦³´XºØ¸ÑÄÀ: 1.«ùÄò©ÊªºÃö¸`·P¬V,¤Î¯f­ì²£ª«º¢¯dÃö¸`µÄ¾É­PÃö¸`ªººC©Êµoª¢. 2.¥Ñ©ó¥i´ú¥Xtype II collagen and heat shock proteins, ªí¥Ü³Q·P¬VªºÃö¸`¹ï¯f­ìÅé²£¥Í¤F§K¬Ì¤ÏÀ³. 3.¯f­ìÅ骺¬Y¨Çºc³y»PÃö¸`·¥¬Û¦ü"molecular mimicry", ¦]¦¹²£¥Í¤F¦ÛÅ骺antigen-antibody reaction. ¬y¦æ²v(Epidemiology) 1.Ãþ­·Àã©ÊÃö¸`ª¢¬ù¬°Á`¤H¤fªº0.8%(0.3-2.1%) 2.¤k©Ê¬°¨k©Êªº¤T­¿. 3.¥@¬É¦U¤HºØ¤Î¦U¦a°ì³£·|±wÃþ­·Àã©ÊÃö¸`ª¢ 4.80%ªº±wªÌ, µo¯f©ó35-50·³¤§¶¡. 5.µo¯f©ó30·³¥H«eªº, ¦û¤£¨ìÁ`¼Æªº10% 6.ª½«Y¿ËÄݦ³Ãþ­·Àã©ÊÃö¸`ª¢ªº±wªÌ»Pª½«Y¿ËÄݨS¦³Ãþ­·Àã©ÊÃö¸`ª¢ªº¤ñ²v¬°4:1. Åã¥Ü»P°ò¦]¦³Ãö(¤×¨äHLA-DR) Ãþ­·Àã©ÊÃö¸`ª¢ªºÁ{§É¯S¼x(Clinical manifestations) °_©l¯gª¬ ¤T¤À¤§¤Gªº¯f¤H¦bÃö¸`¯gª¬¥X²{«e, ºCºC¦a·Pı¥þ¨­µê®z, ¯h²Ö, ­¹¼¤¤£®¶,¦Ù¦×¯kµhµ¥. ³o¨Ç«eÅX¯gª¬, ¦³¥i¯à«ùÄò¼Æ¶g¬Æ¦Ü¼Æ­Ó¤ë¤~¥X²{Ãö¸`µh, ¤@¶}©l¤j³£µo¥Í¦b¤â, µÃ,½¥,¨¬ªºÃö¸`¦Ó¥B¹ïºÙµo§@, ¤Ö©ó10%ªº¯f±wÄÝ©ó«æ©Ê, ¦P®É¨Öµo°ª¿N, ²O¤Ú¤ÎµÊŦ¸~¤j.°¸¦Ó¥X²{¦b¤W³¡ÀV´Õ¦Ó¤Þ°_«áªEµh, ¦ýµ´¤£µo¥Í¦b¯Ý³¡¥H¤Uªº¯á´Õ, ¦]¦¹,¦pªG¦³­Iµh¤Î¸yµhµ´¤£¬OÃþ­·Àã©ÊÃö¸`ª¢ Ãö¸`ªº¯g­Ô 1.³Q«I¥ÇªºÃö¸`·|¸~, µh, ¼ö,À£µh,»øµw,¦ý¤£·|¬õ¸~.±á°_ªºÃö¸`»øµw(morning stiffness)¦³¥i¯à«ùÄò1-2¤p®É. 2.¤âªºÃö¸`¤j³£¥X²{¦bµÃÃö¸`, ´x«üÃö¸`(metacarpophalangeal joint),ªñºÝ«ü°©¶¡Ãö¸`(proximal interphalangeal joint), ­È±oª`·Nªº¬O«Ü¤Ö¥X²{¦b»·ºÝ«ü°©¶¡Ãö¸`(distal interphalangeal joint). 3.Ãö¸`ª¢¤[¤F¤§«á, Ãö¸`¦³¥i¯à²£¥Í¬YºØµ{«×ªºÅÜ«¬.¤ñ¸û­«­nªº¦³: Z deformity:radial deviation at wrist and ulnar deviation of digits Swan-deformity:hyperextention of proximal interphlangeal joint with compensatory flexion of distal interphlangeal joint. Boutonnier deformity: flexion deformity of proximal interphlangeal joint and extension of distal interphlangeal joint. Ãö¸`¥H¥~ªº¯g­Ô ¥Ñ©óÃþ­·Àã©ÊÃö¸`ª¢±`§t°ª¿@«×ªº¦ÛÅé§ÜÅé(autoantibody , especially to the Fc component of immunoglobulin G), ¤]´N¬O©Ò¿×ªºrheumatoid factor, ©Ò¥H±`¦³¤@¨Ç¥þ¨­©Êªº¨ä¥L¯gª¬: 1.Rheumatoid nodule: ¤j³£¦bÃö¸`©P³ò, ¤×¨ä­I­±, 2.Rheumatoid vasculitis: ¾É­PŦ¾¹Ãa¦º, ©PÃ䯫¸gª¢,¥Ö½§¼ìºÅ,Ãa¦º, ¸}³k¤Î¤â«üªºgangrene. 3.pleuropulmonary manifestations:include interstitial fibrosis, pleuropulmonary nodules, pneumonitis, arteritis.





   µoªí¥DÃD ¦^ÂÐ¥DÃD

    yoyo  ¦^ÂЩó  2007/7/1 10:15:35



4. Synovial fluid analysis Ãö¸`²G§e²V¿Bª¬,ÂH«×­°§C, ³J¥Õ½è§t¶q¼W°ª, ¸²µå¿}§t¶q­°§C. polymorphonuclear ¥Õ¦å²y¼W¥[(>2000/ml). X-¥úÀˬd ªì´Áªºx-¥úÀˬdµL¬Æ·N¸q, ¹ï¶EÂ_¨Ã¨S¦h¤jÀ°§U, ¦ý¬O·í¯e¯f¤w¶i¦æ´X¦~¤§«á, x-¥úÀˬd¥i¥H¥Î¨Ó`§PÂ_cartilage destruction¤Îbone erosion ¤w¨ì¤°»òµ{«×¤F. Ãþ­·Àã©ÊÃö¸`ª¢ªºªvÀø¤@¯ëªvÀø­ì«h 1.relief of pain,2.reduction of inflammation,3.protection of articular structures,4.maintenance of function, and 5.control of systemic involvement. ªvÀø¨BÆJ Nonsteroid anti-inflammatory drugs(NSAID) Aspirin ¬O³Ì¦nªº¿ï¾Ü. §Q¥Îaspirin§í¨îcyclooxygenaseªº¬¡©Ê, ¦P®É§í¨î¤Fprostaglandin, prostacyclin, and thromboxanesªº²£¥Í¥H¹F¨ìÂíµh, ®øª¢, ¸Ñ¼öªº¥Øªº. ¦ý¤]¦]¬°§í¨îcyclooxygenaseªº¬¡©Ê¦Ó²£¥Í¤F«Ü¦h°Æ§@¥Î,¥]¬A:¶Ë­G,¹L±Ó,¥Ö½§¬õ¯l,¨Ï¹L±Ó»óª¢,®ð³Ý¥[¼@,§¿¬r¯g, ¦å¤pªO¥\¯à²§±`.¦]¦¹¤@¨Ç·sÃÄ¥u§í¨îcyclooxygenase 2 ¦Ó¤£§í¨îcyclooxygenase 1,´N¤£·|¦³³o¨Ç°Æ§@¥Î¤F. 2. Disease-modifying antirheumatic drug ¥]¬A: gold compounds, D-penicillamine, antimalarials, sulfasalazine.Folic acid antagonist(eg:Methotrexate) «h¬O³Ìªñ³Ì±`¥Îªº³o¤@ÃþªºÃÄ. 3. Glucocorticoid therapy §C¾¯¶qªºGlucocorticoid(<7.5gm/d of prednisolone) ¥i¥H¦³®Äªº±±¨î¯gª¬¤Î©µ½wbone erosionªº®É¶¡. Immunosuppresive therapy¨Ò¦p: azathioprine, cyclophosphamide 5. Surgery Surgery is only applied to severely damaged joints Ãþ­·Àã©ÊÃö¸`ª¢ªº¶¼­¹ª`·N¨Æ¶µ¤Î­¹Àøªk¤¤Âå¿ëÃÒ±q¤¤Â媺Æ[ÂI,Ãþ­·Àã©ÊÃö¸`ª¢¨Ì¨ä¯f±¡ªº»´­«½w«æ,¥i¤ÀÃþ¦p¤U: 1.Àã¼ö·ô ªí²{©óªì´Áªº«æ©Êµo§@´Á,¥X²{Ãö¸`¸~,µh, ¨­¼ö¦³¦½¤£¸Ñ,²Ö±wÃö¸`©}¦ù¤£§Q,±á°_»øµw,·Ðļ,§¿¤Ö¦Ó¥BÃC¦âÅܲ` 2.. ¬r¼ö·ô ¤ñÀã¼ö·ô§ó¬°ÄY­«,¤]¬OÄÝ©ó«æ©Êµo§@,Ãö¸`¸~,¼ö,µh, µo°ª¿N,©È§N,¤ß·Ð,¤f´÷,µÊ¤Î²O¤Ú¸~¤j, §¿¶À«Kµw. 3. ´HÀã·ô µo¥Í©ó¤¤±ß´Á©Î¶§µêÅé½èªº±wªÌ,¨C¹J³±«B§N¤Ñ,·|¥O³oÃþ«¬¯f¤Hµh¤£±ý¥Í,Ãö¸`¼@µh¦ý¤£¨`¼ö, ¸~µÈ»øµwµLªkÅs¦±,¼ö¼Å¥i¥H´î»´¯kµh. 4. ¨xµÇµê·ô µo¥Í©ó±ß´Á,¦]¬°¯f¤[²Ö¤Î¨xµÇ(«D«ü¦èÂ大¨xŦ»PµÇŦ), ³y¦¨°©¬\µ¬µä,Ãö¸`»øµwÅܧÎ, ¨­Åéµê½G, ¥Í¬¡¤£¯à¦Û²z. ¶¼­¹ª`·N¨Æ¶µ Ãþ­·Àã©ÊÃö¸`ª¢ªº±wªÌ¦]ªø´Á¨ü¯fµh§é¿i, ¹ì­¹¤£¦w, ¦]¦¹±wªÌ¥HµêÃÒ¬°¦h,¦Ó¥BÃþ­·Àã©ÊÃö¸`ª¢¥H¥~À㬰¦], ¦]¦¹¶¼­¹¤£©y»I±ç«p¨ý, ¹L©óªo¿°¥H§K¦A¥Í¤ºÀã, §_«h¤º¥~¦X¨¸, ¤Ï¦Ó¹ï¯f±¡¤£§Q. ©Ò¥H­ì«h¤W¶¼­¹À³¥H²M²H¬°¥D. ¤û¥¤,¨§¼ß,¤H°Ñ,¥Õ¤ì¦Õ,¶À¯Ï,·íÂk,¬õ´Ç,¬e§ûÁö¬°Àç¾i¨Î«~, ¦ý¤º¦³Àã¼ö©Î¦Þ­aÖß¿°ªÌ,­¹¤§¤Ï¨Ï¸¡µÈ, ¬Æ¦Ü¤£«ä¶¼­¹. ´H¨¸°¾²±ªÌ:¥i¦h­¹¯õ­»,¦×®Û, ªá´Ôµ¥½Õ¨ý«~. À㨸°¾²±ªÌ:¥i¦h­¹íõ¤¯,¥É¦Ì,¬õ¨§. ¼ö¨¸°¾²±ªÌ:¥i¦h­¹ªàµæ,¦è¥Ê,­W¥Ê,µ·¥Ê, ÅÚ½³,ºñ¨§µ¥. ­¹Àøªk 1. ¬õ¨§µ°:¬õ¨§¤@¨â,¥Õ¦Ì¤G¨â,¥Õ¿}¾A¶q, ¦³°£Àã¼öªº¥\¯à íõ¤¯µ°:íõ¤¯¤@¨â,¾ý¯»¤Ö³\,¬â¿},®Ûªá¾A¶q,§@¦­À\¥Î,¥\¯à²M§QÀã¼ö,°·µÊ°£·ô. ºñ¨§¥P¯ó´ö:µN¦nºñ¨§´ö,¥[¤J¤p¶ô¥P¯óÁû²É,°µ¬°²¢ÂI. ´HÀã·ô­¹Àøªk¥ÍÁ¤¤j½µ´ö:¥ÍÁ¤,¤j½µ,»¶´Ô¦U¤T¿ú,¦PÄѱøµN,¶X¼ö¦Y,¥H¥X¦½¬°«×,¥\¯à¸Ñªí´²´H. 3.´H¼ö¿ù¬V·ô«¬­¹Àøªk ¥Õ¤ì¦Õ®Û¶ê´ö:¥Õ¤ì¦Õ¤@¨â,®Û¶ê¤G¨â,¥ý±N¥Õ¤ì¦Õ¥h¸¦¬~²b,µNªm«á¿LµN¦Ü¥b¶p,¤J®Û¶ê¦×,¦A¦@µN¦Ü¥Õ¤ì¦Õ³n,®Û¶ê¦×§¡¥X¨ý¬°«×,¤À¼Æ¤éªA¥Î. 4.¨xµÇ³±µê­¹Àøªk ®áÝÒ¤lµ°:¥H®áÝÒ¤l©M¸e¦ÌµN¦¨µ°,±`ªA¦¹µ°,±j¨xµÇ,ª¬¨­Åé. ¦ó­º¯Qµ°:¦ó­º¯Q¤@¨â,¸e¦Ì¤@¨â,¬õ´Ç¤­¿ú,¬õ¿}¾A¶q,¥ý±N¦ó­º¯Q·ÎµN¨ú²G¥Ä,¥h´í,±N¸e¦Ì,¬õ´Ç¦P¤J¬âÁçµN¦¨µ°,©ñ¤J¤Ö³\¬õ¿}½Õ¨ý,¦AµN¤@,¤Gªm,§Y¥i­¹¥Î,¦ó­º¯Q¨ã¦³¾i¦å´þ³±,¸É¨x¯qµÇªº§@¥Î ¨xµÇ¶§µê­¹Àøªk ³À¯ñ°s:³À¯ñ¤@¨â,¤sÃĤG¨â,¦Ì°s¤@¤ç,±N³À¯ñ,¤sÃÄ®ûªw¦b¦Ì°s¤¤,«Ê©T¤T¤Q¤Ñ«á¶¼¥Î,¨C¦¸¤@¤pªM. ·íÂk¥ÍÁ¤¦Ï¦×´ö:·íÂk¤T¿ú,Á¤¤@¨â,¦Ï¦×¾A¶qµN´ö. ¤Q¥þ¤j¸É´ö:¤H°Ñ(8gm),¦×®Û¥h¥Ö(8gm),¤tË|(5gm),¦a¶À°s¬~»]µH(8gm),Ó¬­dµH(8gm),¥Õ§ô(8gm),¥Ì¯ó¨b(5gm),¶À¯Ï¥hĪ(15gm), ¤t·íÂk¬~,¥hĪ(10gm),¥Õ¨¢(8gm), ¦³·Å¸É®ð¦åªº¥\¥Î.





   µoªí¥DÃD ¦^ÂÐ¥DÃD

¦@  1  ­¶    ¥Ø«e  1      «e©¹¡G  ¿é¤J¼Æ¦r«öEnter

¤ý®v¤÷±M·~Àð¾À¤Á¤ÕÆp¤Õ¤Þ¤Õ¤uµ{ªA°È
¥x¥_Æp¤Õ¤Á³Î ¤T­«Æp¤Õ¤Á³Î
ªO¾ôÆp¤Õ¤Á³Î ·s²øÆp¤Õ¤Á³Î
Àð¾ÀÆp¤Õ¤Á³Î,Àð­±¤Þ¤ÕÆp¤Õ,¦aªOÆp¤Õ¤Á³Î

[±ÀÂ˵û»ù¦n©±] - 4C§Ö­×³sÂêªù¥« ±M·~ºû­×¶R½æ-µ§¹q+¤â¾÷+¹q¸£+Iphone+Ipad
·s¥_¦Á¤î©± (02) 7751-9182
·s¥_¥«¦Á¤î°ÏºÖ¼w¤@¸ô86«Ñ22¸¹
·s¥_ªO¾ô©± (02) 8257-3990
·s¥_¥«ªO¾ô°Ï¥|ºû¸ô137«Ñ10¸¹
®ç¶é¤j·Ë©± (03) 387-4353
®ç¶é¥«¤j·Ë°Ï¤¤µØ¸ô210¸¹
¥x¤¤¥«°Ï©± (04) 2201-1289
¥x¤¤¥«¤¤°Ï¥x¤¤¸ô140¸¹


   ¥xÆWÂåÀø½×¾Â ¦^³»ºÝ
¦Û¾AÀ³ºô­¶½d¥»


³sµ²Àu¨}¸ê°T¤J¤fºô ¥»¯¸¤J³ò½Ã¥Í¸p95¦~«×Àu¨}°·±d¸ê°Tºô¯¸ ¥xÆWÂåÀøºô © 2006 Taiwan Inc. All Rights Reserved.

*«ØÄ³IE5.0¥H¤W¤§ÂsÄý¾¹ ¸ÑªR1024*768 ¥H¹F³Ì¨ÎÂsÄý®ÄªG* ¥þ¯¸¨Ì¤º®e¤À¯Å³W©w³B²z